TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: frequency rate of drug‐associated fever
Endpoint domain: Adverse events/effects
Primary endpoint: nephrotoxicity (increase of serum creatinine concentration)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the serum concentration-time curve from zero to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of Namilumab
Endpoint domain: Adverse events/effects
Primary endpoint: FAB scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacterial Vaginosis (BV) prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: interleukin 6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: soluble tumor necrosis factor alpha receptor 1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CAPS score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutrophil-to-lymphocyte ratio (NLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ETTc pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of air to inflate ETTc
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immune responses measured in the peripheral blood lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Response inhibition impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Episodic memory impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Schizophrenic-like and dissociative symptoms increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: immunization pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day all-cause mortality or re-hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: change in overall pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in medial tibial cartilage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Competency in asthma severity classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreasing lesion area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreasing pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life outcomes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Quality of life outcomes
Endpoint domain: Life impact
Endpoint subdomain: Bodily pain
Primary endpoint: SA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of children wearing spectacles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma umeclidinium or vilanterol systemic exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of umeclidinium excreted in 24 hours in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Exposure to hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: impairment of memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: prolonged reaction times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Body fat correlation with appendicular BMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma d9‐betaine:d9‐phosphatidylcholine (PC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma d3‐choline:d3‐PC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEMT‐PC enrichment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SDF-1 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: JNK phosphorylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean stromal bed thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean difference between actual and predicted central ablation depths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes with posterior stromal beds thicker than 250 microm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of infection (chorioamnionitis + endometritis)
Endpoint domain: Adverse events/effects
Primary endpoint: Functional competence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lower-limb aerobic exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for IOL implant versus CL correction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of return visits for acute asthma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: GGT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: AP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: ALT values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Cervicovaginal HIV-1 RNA loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma HIV-1 RNA loads
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: OHQ composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upright systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dizziness/lightheadedness score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal fall in FEV1 <10% after EVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: group mean symptom scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IgG concentrations ≥0.35 µg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean device difference in pupil diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Outlier frequency at 1 lux and 7 lux
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TLNS = 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLNS = 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGII score of 4 (completely improved)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression of age-related macular degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of hikers without injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Mean foot temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medium time of effective therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of smokers receiving cessation support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary DPD excretion levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum OC levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rebound intraocular hypertensive effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sodium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: chloride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: E. coli inhibitory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical and endoscopic recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of proven or possible infections
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal permeability index (IPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satiety ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced energy intakes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen desaturation incidence
Endpoint domain: Adverse events/effects
Primary endpoint: erosion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: joint space narrowing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total duration of UPJ repair and anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Index of microcirculatory resistance (IMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unaided visual acuity (UDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aided visual acuity (CDVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spherical aberration induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial 2-h glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA(1c) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of severe hypoglycemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Evacuation function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reservoir function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cervical cancer screening rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-stress LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Summed stress score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visual Acuity (VA) decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective blur
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in DLCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Delayed Pulmonary Toxicity Syndrome (DPTS)
Endpoint domain: Adverse events/effects
Primary endpoint: Perception of fullness 5 min after the meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perception of pain at 5 min, 10 min, and 25 min after the meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intragastric proximal/distal meal distribution ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete remission (CR) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated vasodilatation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intensity of pain as per VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tenderness as per digital pressometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Function-Erectile Function domain improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic girdle pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction with medical visits
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brunet Lézine score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to use NPS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expectations regarding NPS use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived vulnerability to NPS use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Impact on pregnancy knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reported attitudes to sex
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Modified Oswestry Low Back Pain Disability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Physical function and role limitations (Short‐Form 36 Health Survey)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Dosing cup use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regress of inflammation at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of PC-BPPV symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HbA(1c) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rates of intra-abdominal infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of telemedical HBP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between HBP and ABP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Uterine blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: 24-hour mean blood pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-hour diastolic blood pressure decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: nocturnal blood pressure dipper pattern improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ongoing pregnancy rate (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: twin pregnancy rate (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Quality of performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of patients with major flare at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: St Mark's score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD symptom severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: therapeutic effect for treating cervical vertigo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of immediate wheal and flare reactions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Shorter time till recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's total cycling skill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Body Mass Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration–time curve for capecitabine and its metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final PCI success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative neuropathy
Endpoint domain: Adverse events/effects
Primary endpoint: VO₂peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to recovery from sensory block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median onset time of T10 analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average ephedrine required to treat hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: 50% reduction in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete remission from depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: health-related quality-of-life improvements
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Median effective dose (ED50) of phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TA plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colon cleansing scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma detection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Lipoprotein(a) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total cholesterol/HDL-cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correct interpretation of treatment benefits
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: VAS score in the PACU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient acceptance of study invite
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trabecular BMD increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Cortical thickness decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Cortical porosity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Incidence of delayed graft function (DGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Creatinine clearance up to 1 month after transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: naive CD4+ cell percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: memory CD4+ cell percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: activated CD8+ cell percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patient-centred follow-up care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage LDL-C reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean post-treatment LDL-C values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean change in plasma tHcy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvements in diabetes care delivery
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Improvements in psychosocial outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Early reperfusion therapy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in maximal plaque area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: oxidative stress index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in S‐COMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum number of cigarettes smoked in a single day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of signs and symptoms of inflammatory arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delay in radiological progression of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of postoperative sore throat
Endpoint domain: Adverse events/effects
Primary endpoint: Self-reported abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically verified abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 general health score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average CMV-associated costs per patient
Endpoint domain: Resource use